BeOne Medicines (ONC) vs Vertex Pharmaceuticals (VRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vertex Pharmaceuticals (VRTX) has outperformed BeOne Medicines (ONC) over the past year, gaining 23.2% versus a gain of 6.6%. Over five years, VRTX leads with a +178.2% price change compared with +1.6% for ONC. Vertex Pharmaceuticals is the larger company by market cap ($127.51 billion vs $38.78 billion), about 3.3 times the size, while BeOne Medicines is growing revenue faster (+40.2% vs +8.9%).
On valuation, Vertex Pharmaceuticals trades at a lower forward P/E (25.0x vs 33.2x for BeOne Medicines). Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | VRTX |
|---|---|---|
| Share price | $340.85 | $503.08 |
| Market cap | $38.78B | $127.51B |
| 1-day change | -6.37% | -0.51% |
| YTD return | +19.82% | +11.53% |
| 1-year return | +6.56% | +23.24% |
| 5-year return | +1.56% | +178.18% |
| P/E ratio (TTM) | 60.97 | 29.30 |
| Forward P/E | 33.25 | 25.01 |
| EPS (TTM) | $5.59 | $17.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.34B | $12.00B |
| Revenue growth (YoY) | +40.23% | +8.90% |
| Net income (latest FY) | $286.93M | $3.95B |
| Gross margin | 87.49% | 86.24% |
| Operating margin | 8.37% | 34.77% |
| Net margin | 5.37% | 32.94% |
| 52-week high | $385.22 | $560.25 |
| 52-week low | $253.95 | $402.58 |
| Distance from 52-week high | -11.52% | -10.20% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +27.68% | +13.58% |
| Average volume | 388.88K | 1.16M |
| Shares outstanding | 104.92M | 253.46M |
| Employees | 12,000 | 6,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vertex Pharmaceuticals is about 3.3 times larger than BeOne Medicines by market value ($127.51B vs $38.78B).
- VRTX has outperformed ONC by 16.7 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (61.0x vs 29.3x trailing P/E).
- Vertex Pharmaceuticals is more profitable, keeping 32.9 cents of every revenue dollar as net income versus 5.4 cents for BeOne Medicines.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs +8.90%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About Vertex Pharmaceuticals
VRTX stock →Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees
ONC vs VRTX FAQ
Which is bigger, BeOne Medicines or Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) is larger, with a market capitalization of $127.51B compared with $38.78B for BeOne Medicines (ONC).
Which stock has performed better over the past year, ONC or VRTX?
VRTX returned +23.24% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ONC or VRTX?
VRTX has the lower trailing P/E at 29.3, versus 61.0 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BeOne Medicines and Vertex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.